New studies reveal crucial insights into cancer therapy and resistance mechanisms. One investigation utilizes cutting-edge single-cell and spatial omics to dissect breast cancer tumor microenvironment dynamics during neoadjuvant treatment. Another unveils innovative use of PD-L1 siRNA to enhance immunotherapy efficacy by disrupting tumor immune evasion. Additional research emphasizes the vital role of non-coding RNAs in modulating cancer cell sensitivity to Topotecan chemotherapy, expanding understanding of gene regulation in drug response. These findings collectively inform future therapeutic strategies.